Boston Scientific management check

BSX · Health Care · Health Care Equipment · CEO Michael F. Mahoney

Filings as of

68
Management score, ranked 199th of 487 · 23rd of 60 in Health Care4 good · 2 to watch · 1 flaggedStrongest: owner returns · Weakest: dilution · Best and worst run in Health Care →

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$265Peers$148

    What $100 became since fiscal 2021

    100100th
    Detail

    $100 invested at the start of fiscal 2021 grew to $265, against $148 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8454th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.68 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.8% of net income

    $23.5m pay · $2.9bn net income, FY2025

    0.1%1%3%10%
    5758th
    Detail

    $23.5m of reported pay in fiscal 2025, against $2.9bn of net income.

  • Good

    Do they own the stock?

    Insiders are buying

    252,241 shares

    6 mo: ▲ $9.5m bought · ▼ $0 sold

    8095th
    Detail

    4 insiders bought $9.5m on the open market in the last six months, with their own money, near the lows.

  • Watch

    Are owners being diluted?

    Share count growing2021 · 1.4bn2025 · 1.5bn

    Diluted shares +1.1% a year; flagged above +2%

    0%10%20%

    Stock pay 1.5% of revenue

    3719th
    Detail

    Diluted shares changed +1.1% a year over the last three fiscal years. Stock-based pay was 1.5% of revenue in the latest year.

  • Flag

    Is leadership stable?

    15 leadership filings in 3 years

    15 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Michael F. Mahoney

    5025th
    Detail

    CEO in the pay table: Michael F. Mahoney. 15 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Watch

    Are the books clean?

    An annual report was amended

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 110-K amended
    7015th
    Detail

    No restatements, auditor changes or late filings since 2021. 1 amended annual report.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 18, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$32.9m$65.8m$10020212022202320242025$265$148

Pay tied most to Adjusted Net Sales

Other key measuresAdjusted Net Sales*Adjusted EPS*Adjusted OIM*Organic Net Sales Growth*Relative Total Shareholder Return

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Michael F. Mahoney$23.5m$33.0m$5.8m$265$148$2.9bn
2024Michael F. Mahoney$21.4m$65.8m$5.5m$248$129$1.8bn
2023Michael F. Mahoney$18.7m$38.6m$4.9m$161$126$1.6bn
2022Michael F. Mahoney$16.9m$21.6m$4.9m$129$124$698.0m
2021Michael F. Mahoney$16.1m$20.4m$3.9m$118$126$1.0bn

Insiders and the CEO's stakeBuying

Chairman, President & CEO
Michael F Mahoney
Shares held
252,241
Latest Form 4
Nov 4, 2026

4 insiders bought $9.5m on the open market in the last six months, with their own money, near the lows.

Open-market trades by officers and directors since May 21, 2026.

  • BoughtMichael F MahoneyChairman, President & CEO$9.0mAug 3, 2026
  • BoughtEdward J LudwigDirector$227kJul 31, 2026
  • BoughtDavid C HabigerDirector$157kAug 5, 2026
  • BoughtSusan E MoranoDirector$100kAug 25, 2026

Leadership and governance on file

20222023202420252026Leadership 21Red flags 1Votes 5
All 22 filings

Latest shareholder vote results: May 5, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $138.0m returned to owners in buybacks and dividends, and $1.2bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$149.5m$299.0m20212022202320242025Shares1.43bn1.44bn1.46bn1.49bn1.49bn
Show the figures
Fiscal year20212022202320242025
Revenue$11.9bn$12.7bn$14.2bn$16.7bn$20.1bn
Net income—————
Stock-based pay$194.0m$220.0m$233.0m$266.0m$299.0m
Buybacks$0$0———
Dividends$55.0m$55.0m$28.0m$0—
Diluted shares1434m1440m1464m1486m1495m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.